Skip to content
Austin Top 50
Author:
Phrontline Biopharma
Phrontline Biopharma Highlights Encouraging Preliminary Safety and Antitumor Activity of TJ101 Presented at ESMO 2026 and Announces Phase Ib Initiation
October 29, 2026
Phrontline Biopharma Doses First Patient in Global Phase I/II Trial of TJ102, an FRα × CDH6 Bispecific Dual-Payload ADC
September 30, 2026